Severely worsening dyspnea after initiation of macitentan therapy for pulmonary arterial hypertension

Int J Cardiol. 2016 Jan 1:202:244-5. doi: 10.1016/j.ijcard.2015.08.132. Epub 2015 Sep 14.

Authors

Micha T Maeder¹, Rebekka Kleiner², Daniel Weilenmann³

Affiliations

¹ Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. Electronic address: Micha.maeder@kssg.ch.
² Department of Pulmonary Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland.
³ Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

PMID: 26402452
DOI: 10.1016/j.ijcard.2015.08.132

No abstract available

Keywords: Left ventricular diastolic function; Macitentan; Pulmonary hypertension.

Publication types

Case Reports
Letter

MeSH terms

Aged
Dyspnea / chemically induced*
Dyspnea / physiopathology
Endothelin A Receptor Antagonists / administration & dosage
Endothelin A Receptor Antagonists / adverse effects
Female
Humans
Hypertension, Pulmonary / drug therapy*
Hypertension, Pulmonary / physiopathology
Pyrimidines / administration & dosage
Pyrimidines / adverse effects*
Sulfonamides / administration & dosage
Sulfonamides / adverse effects*

Substances

Endothelin A Receptor Antagonists
Pyrimidines
Sulfonamides
macitentan